The pneumococcal Advance Market Commitment (AMC) is an innovative way to make effective and affordable pneumococcal vaccines available for children in developing countries.
The AMC provides incentives for manufacturers to produce large quantities of pneumococcal vaccine which can then reach developing countries as much as a decade earlier than they historically would have done. The AMC is funded by Canada, Italy, Norway, the Russian Federation, the United Kingdom and the Bill & Melinda Gates Foundation.
Read the 2012 Pneumococcal AMC Annual Report. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.